Dynamics of clinical manifestations of irritable bowel syndrome against the background of cytoprotector rebamipide intake: intermediate results of the SOKRAT program
- Authors: Simanenkov V.I.1, Bakulina N.V.1, Nekrasova A.S.1, Elokhina E.A.1, Topalova Y.G.1
-
Affiliations:
- North-West State Medical University named after I.I. Mechnikov
- Issue: Vol 13, No 3 (2021)
- Pages: 75-82
- Section: Original research
- URL: https://journal-vniispk.ru/vszgmu/article/view/88094
- DOI: https://doi.org/10.17816/mechnikov88094
- ID: 88094
Cite item
Abstract
BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common diseases of the gastrointestinal tract, the detection rate of which in the general population is 9-23%, in the Russian Federation – 8.3-19%. IBS is the cause of chronic pain which accompanies patients throughout their life, significantly reducing its quality and disrupting social adaptation. Insufficient effectiveness of modern methods of treating IBS dictates the need to search for new drugs, the pharmacological action of which is aimed at the pathogenetic mechanisms of IBS formation. Currently, more and more attention in the development of IBS is paid to the syndrome of increased epithelial permeability, in connection with which it is promising to include the universal cytoprotector rebamipide in the complex therapy of patients with IBS.
AIM: To evaluate the effect of rebamipide on the course of irritable bowel syndrome.
MATERIALS AND METHODS: This article presents the intermediate results of the SOCRAT study, which has assessed the effect of rebamipide on the course of IBS. For this purpose, 40 patients with IBS have been examined and subsequently randomized into two groups comparable in gender, age and type of IBS. The patients of the main group (n = 21) received cytoprotector rebamipide in addition to standard antispasmodic therapy, and the patients of the comparison group (n = 19) received cytoprotector bismuth tripotassium dicitrate. Patients’ gastroenterological complaints have been assessed before and after treatment using GSRS, 7x7, IBS-QOL questionnaires and a visual analogue scale.
RESULTS: According to the study findings, the well-being of the patients has improved in the both study groups. However, more significant positive dynamics has been observed in the main group, as evidenced by a significant decrease in the frequency and severity of abdominal pain and symptoms caused by constipation, which, in turn, led to an increase in the quality of life of the studied patients.
CONCLUSIONS: Thus, protective therapy of epithelium with rebamipide has not only a symptom-reducing effect, but also a positive effect on the course of IBS.
Full Text
##article.viewOnOriginalSite##About the authors
Vladimir I. Simanenkov
North-West State Medical University named after I.I. Mechnikov
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1956-0070
SPIN-code: 8073-2401
MD, Dr. Sci. (Med.), Professor
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015Natalya V. Bakulina
North-West State Medical University named after I.I. Mechnikov
Email: nv_bakulina@mail.ru
ORCID iD: 0000-0003-4075-4096
SPIN-code: 9503-8950
Scopus Author ID: 7201739080
ResearcherId: N-7299-2014
http://www.researcherid.com/rid/N-7299-2014
MD, Dr. Sci. (Med.)
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015Anna S. Nekrasova
North-West State Medical University named after I.I. Mechnikov
Email: annanekrasova@list.ru
SPIN-code: 7502-5036
MD, Cand. Sci. (Med.)
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015Evgeniya A. Elokhina
North-West State Medical University named after I.I. Mechnikov
Email: kopiuti1995@gmail.com
врач-терапевт приемного отделения клиники Э.Э. Эйхвальда
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015Yuliya G. Topalova
North-West State Medical University named after I.I. Mechnikov
Author for correspondence.
Email: topalova.julias@yandex.ru
ORCID iD: 0000-0003-3999-6848
SPIN-code: 1301-6443
MD
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015References
- Aziz I, Palsson OS, Törnblom H, et al. The Prevalence and impact of overlapping rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a cross-sectional general population study in three countries. Am J Gastroenterol. 2018;113(1):86–96. doi: 10.1038/ajg.2017.421
- Ambulatornaya gastroenterologiya. Rukovodstvo dlya vrachej. Ed. by I.G. Bakulin. Moscow; 2020. (In Russ.)
- Ardatskaya MD, Topchy TB, Loschinina YuN, Kalashnikova MA. Clinical efficiency of butyric acid and inulin in rapid relief of pain syndrome in patients with irritable bowel syndrome. Lechaschi Vrach. 2015;(12):79–86. (In Russ.)
- Pushkina AV, Avalueva EB, Vorobiev SL. Immunohistochemical characteristics of the colonic mucosa in patients with irritable bowel syndrome. Gastroenterology of St. Petersburg. 2020;(3–4):3–12. (In Russ.)
- El Serag HB, Olden K, Bjorkman D. Healthrelated quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16(6):1171–1185. doi: 10.1046/j.1365-2036.2002.01290.x
- Baranovsky AYu, Wasserman LI, Fedorova VL, Chugunov DN. Irritable bowel syndrome: clinical, psychological and psychosocial interdependence. Experimental and Clinical Gastroenterology. 2019;(12(172)):3. (In Russ.). doi: 10.31146/1682-8658-ecg-172-12-34-39
- Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):121–278. (In Russ.). doi: 10.15829/1728-8800-2021-2758
- Klinicheskie rekomendacii. Sindrom razdrazhennogo kishechnika. 2021–2023 [Internet]. Minzdrav RF. Available from: https://legalacts.ru/doc/klinicheskie-rekomendatsii-sindrom-razdrazhennogo-kishechnika-utv-minzdravom-rossii/. Accessed: Sep 15, 2021. (In Russ.)
- Sheptulin A, Vize-Khripunova MA. Review of Rome-IV criteria for the irritable bowel syndrome: are there any basic changes? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):99–103. (In Russ.). doi: 10.22416/1382-4376-2016-26-5-99-103
- Ivashkin VT, Shelygin YA, Baranskaya EK, et al. Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of irritable bowel syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76–93. (In Russ.). doi: 10.22416/1382-4376-2017-27-5-76-93
- Barbalho SM, Goulart RA, Araújo AC, et al. Iirritable bowel syndrome: a review of the general aspects and the potential role of vitamin D. Expert Rev Gastroenterol Hepatol. 2019;13(4):345–359. doi: 10.1080/17474124.2019.1570137
- Ivashkin VT, Zolnikova OYu. Irritable bowel syndrome in terms of changes in the microbiota. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):84–92. (In Russ.). doi: 10.22416/1382-4376-2019-29-1-84-92
- Andreev DN. The role of alterations in permeability of the intestinal mucosa in the genesis of functional gastrointestinal disorders. Consilium Medicum. 2019;21(8):29–34. (In Russ.). doi: 10.26442/20751753.2019.8.190539
- Casado-Bedmar M, Keita AV. Potential neuro-immune therapeutic targets in irritable bowel syndrome. Therap Adv Gastroenterol. 2020;13:1756284820910630. doi: 10.1177/1756284820910630
- Choghakhori R, Abbasnezhad A, Hasanvand A, Amani R. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine. 2017;93:34–43. doi: 10.1016/j.cyto.2017.05.005
- Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. Neurogastroenterol Motil. 2016;22(4):558–574. doi: 10.5056/jnm16001
- Farré R, Vanheel H, Vanuytsel T, et al. In functional dyspepsia, hypersensitivity to postprandial distention correlateswwith mealrelated symptom severity. Gastroenterology. 2013;145(3):566–573. doi: 10.1053/j.gastro.2013.05.018
- Ludidi S, Mujagic Z, Jonkers D, et al. Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2014;26(8):1104–1111. doi: 10.1111/nmo.12365
- Kanazawa M, Palsson OS, Thiwan SМ, et al. contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008;103(10):2550–2561. doi: 10.1111/j.1572-0241.2008.02066.x
- Coss-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. Curr Gastroenterol Rep. 2014;16(4):379. doi: 10.1007/s11894-014-0379-z
- Johansso MEV, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–361. doi: 10.1038/nrgastro.2013.35
- Simanenkov VI, Lutaenko EA, Nikogosyan AA. Clinical and pharmacological characteristics of rebamipide in deseases of the gastrointestinal tract. Medical Council. 2016;(19):88–95. (In Russ.). doi: 10.21518/2079-701X-2016-19-88-95
- Simanenkov VI, Tikhonov SV. Rebamipide: new opportunities for gastroenteroprotection. Therapeutic Archive. 2015;87(12):134–137. (In Russ.). doi: 10.17116/terarkh20158712134-137
- Punkina AV, Avalueva EB, Ellinidi VN, et al. Optimizatsiya nekotorykh pokazateley lokal’nogo immuniteta patsientov s sindromom razrazhennogo kishechnika pri lechenii preparatom vismuta. Gastroenterologiya Sankt-Peterburga. 2016;(1–2):11–14. (In Russ.)
- Punkina AV, Avalueva EB, Danilova IA, et al. Ispol’zovanie preparatov vismuta trikaliya ditsitrata v lechenii sindroma razdrazhennogo kishechnika s preobladaniem diarei. Lechashchiy vrach. 2016;6:81–84. (In Russ.)
- Simanenkov VI, Bakulina NV, Tikhonov SV. Bismuth tripotassium dicitrat: from pharmaceutical characteristics to clinical efficacy. Medical Alphabet. 2019;1(6(381)):23–28. (In Russ.). doi: 10.33667/2078-5631-2019-1-6(381)-23-28
- Tkachenko EI, Avalueva EB, Sitkin SI, et al. Ispol’zovanie preparatov vismuta v lechenii sindroma razdrazhennogo kishechnika. Gastroenterologiya Sankt-Peterburga. 2013;(3–4):11–14. (In Russ.)
- Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49(2):202–209. doi: 10.1023/b:ddas.0000017439.60943.5c
- Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5–13.
- Nishizawa T, Suzuki H, Nakagawa I, et al. Rebamipide - promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259–262. doi: 10.1159/000213241
- Suzuki T, Yoshida N, Nakabe N, et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469–477. doi: 10.1254/jphs.fp0071422
Supplementary files
